US4663167A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition and method for treatment of disseminated fungal infections in mammals
Assignee: The University of Texas System
•
Filing: 1984-04-16
•
Granted: 1987-05-05
•
Expires: 2004-04-16
Abstract
Abstract Method for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising liposome-encapsulated Amphotericin B, said liposome being comprised of lipids other than sterols.
Inventors
- 👤 Gabriel Lopez-Berestein
- 👤 Victor Fainstein
- 👤 Evan M. Hersh
- 👤 Roy L. Hopfer
- 👤 Rudolph L. Juliano
- 👤 Kapil Mehta
- 👤 Reeta Mehta
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 20:41
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K31/00; A61K31/70; A61K31/7042; A61K31/7048; Y; Y10; Y10T; Y10T428/00; Y10T428/29; Y10T428/2982; Y10T428/2984
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
45 words
A method for treating disseminated fungal infection in a mammal comprising administering to a mammal a fungicidally effective amount of Amphotericin B encapsulated in a liposome which is substantially sterol-free and consists essentially of dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol in an approximately 7:3 molar ratio.
Claim 2
Independent Claim
45 words
A method for treating disseminated fungal infection in a mammal comprising administering to a mammal a fungicidally effective amount of Amphotericin B encapsulated in a liposome which is substantially sterol-free and consists essentially of dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol in an approximately 7:3 molar ratio.
Claim 3
Dependent Claim
12 words
The method of claim 1, where the liposome is a multi-lamellar liposome.
Claim 4
Dependent Claim
11 words
The method of claim 1, where the mammal is a human.
Claim 5
Dependent Claim
35 words
The method of claim 1, where the fungicidally effective amount of Amphotericin B is between about 0.4 milligrams of Amphotericin B per kilogram of body weight to about 4.0 milligrams per kilogram of body weight.
Claim 6
Dependent Claim
38 words
A therapeutic agent for treating disseminated fungal infection in a mammal, comprising Amphotericin B encapsulated within a liposome, the liposome being substantially sterol-free and consisting essentially of dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol in an approximately 7:3 molar ratio.
Claim 7
Dependent Claim
38 words
A therapeutic agent for treating disseminated fungal infection in a mammal, comprising Amphotericin B encapsulated within a liposome, the liposome being substantially sterol-free and consisting essentially of dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol in an approximately 7:3 molar ratio.
Claim 8
Dependent Claim
13 words
The therapeutic agent of claim 5, where the liposome is a multilamellar liposome.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-04 | 1990-11-03 | 1991-05-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-04 | 1994-11-03 | 1995-05-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-04 | 1998-11-03 | 1999-05-05 | $7700.00 | Window Closed / Lapsed |